Richard Hansen - Septerna, Common Vice Technology
| SEPN Stock | 24.76 0.53 2.10% |
Executive
Richard Hansen is Vice Technology of Septerna, Common Stock
| Address | 250 East Grand Avenue, South San Francisco, CA, United States, 94080 |
| Phone | 650 338 3533 |
| Web | https://septerna.com |
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Patric MBA | Viracta Therapeutics | N/A | |
| Biljana PharmD | Viracta Therapeutics | N/A | |
| Seth Harmon | Viridian Therapeutics | 44 | |
| Joakim Wijkstrom | Vanda Pharmaceuticals | 58 | |
| Doug BA | Dyadic International | N/A | |
| Gabriela Jairala | Vincerx Pharma | N/A | |
| Stewart Brown | Viracta Therapeutics | N/A | |
| Jennifer JD | Viridian Therapeutics | 52 | |
| Nina Devlin | Vertex Pharmaceuticals | N/A | |
| Michael Morneau | Viking Therapeutics | 59 | |
| Ralph MPH | Dogwood Therapeutics, | 55 | |
| Jonathan JD | Vertex Pharmaceuticals | 60 | |
| Robert McRae | Viracta Therapeutics | N/A | |
| Susie CFA | Vertex Pharmaceuticals | N/A | |
| Shan Wu | Viridian Therapeutics | N/A | |
| Angela Walsh | Dogwood Therapeutics, | 58 | |
| Carol Duffy | Dogwood Therapeutics, | N/A | |
| Karen MBA | Vincerx Pharma | N/A | |
| Susie Lisa | Vertex Pharmaceuticals | N/A | |
| Melissa Manno | Viridian Therapeutics | N/A | |
| Anthony Casciano | Viridian Therapeutics | 47 | |
Septerna, Common Stock Leadership Team
Elected by the shareholders, the Septerna, Common's board of directors comprises two types of representatives: Septerna, Common inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Septerna,. The board's role is to monitor Septerna, Common's management team and ensure that shareholders' interests are well served. Septerna, Common's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Septerna, Common's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert MD, CoFounder Board | ||
| Daniel DPHIL, Senior Discovery | ||
| MS MBA, Chief Officer | ||
| Uwe Klein, Senior Sciences | ||
| Arthur BPHARM, CoFounder Board | ||
| Richard Hansen, Vice Technology | ||
| David Martin, Senior Sciences | ||
| Samira Shaikhly, Chief Officer | ||
| George Xu, Senior Strategy | ||
| MBA CFA, Interim Operations | ||
| Patrick Sexton, CoFounder Board |
Septerna, Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Septerna, Common a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Total Debt | 169.24 M | ||||
| Number Of Employees | 68 | ||||
| Total Asset | 130.87 M | ||||
| Retained Earnings | (46.58 M) | ||||
| Working Capital | 105.76 M | ||||
| Net Asset | 130.87 M |
Pair Trading with Septerna, Common
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Septerna, Common position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Septerna, Common will appreciate offsetting losses from the drop in the long position's value.Moving against Septerna, Stock
The ability to find closely correlated positions to Septerna, Common could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Septerna, Common when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Septerna, Common - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Septerna, Common Stock to buy it.
The correlation of Septerna, Common is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Septerna, Common moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Septerna, Common Stock moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Septerna, Common can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Septerna, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Septerna, Common. If investors know Septerna, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Septerna, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Septerna, Common Stock is measured differently than its book value, which is the value of Septerna, that is recorded on the company's balance sheet. Investors also form their own opinion of Septerna, Common's value that differs from its market value or its book value, called intrinsic value, which is Septerna, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Septerna, Common's market value can be influenced by many factors that don't directly affect Septerna, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Septerna, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Septerna, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Septerna, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.